ARK Investment Management LLC Sells 155,582 Shares of COMPASS Pathways PLC Sponsored ADR $CMPS

ARK Investment Management LLC trimmed its position in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 8.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,649,221 shares of the company’s stock after selling 155,582 shares during the period. ARK Investment Management LLC’s holdings in COMPASS Pathways were worth $4,618,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of CMPS. Nantahala Capital Management LLC boosted its holdings in COMPASS Pathways by 182.9% in the 1st quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company’s stock valued at $8,092,000 after purchasing an additional 1,829,232 shares during the period. Vivo Capital LLC raised its position in shares of COMPASS Pathways by 109.1% during the 1st quarter. Vivo Capital LLC now owns 3,362,385 shares of the company’s stock valued at $9,616,000 after buying an additional 1,754,385 shares in the last quarter. Woodline Partners LP raised its position in shares of COMPASS Pathways by 279.9% during the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company’s stock valued at $5,019,000 after buying an additional 1,292,927 shares in the last quarter. Driehaus Capital Management LLC purchased a new stake in shares of COMPASS Pathways during the 1st quarter valued at $2,007,000. Finally, 22NW LP purchased a new stake in shares of COMPASS Pathways during the 1st quarter valued at $1,849,000. 46.19% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CMPS. Canaccord Genuity Group restated a “buy” rating and set a $15.00 price objective on shares of COMPASS Pathways in a research report on Friday, August 1st. HC Wainwright decreased their target price on shares of COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, August 4th. BTIG Research lifted their target price on shares of COMPASS Pathways from $7.00 to $14.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.00.

COMPASS Pathways Price Performance

Shares of COMPASS Pathways stock opened at $6.34 on Thursday. The firm has a market cap of $608.26 million, a PE ratio of -3.45 and a beta of 2.21. COMPASS Pathways PLC Sponsored ADR has a 12-month low of $2.25 and a 12-month high of $7.09. The company has a quick ratio of 8.82, a current ratio of 8.82 and a debt-to-equity ratio of 0.16. The company’s fifty day simple moving average is $5.38 and its two-hundred day simple moving average is $4.40.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). As a group, equities analysts expect that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.